Responses
EULAR 2014: Scientific Abstracts
Oral Presentations. Abstract session: Genes, disease activity and treatment of psoriatic arthritis
OP0078 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-WEEK) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials
Compose a Response to This Article
Other responses
No responses have been published for this article.